Andrew Geall

Andrew Geall

Company: Replicate Bio

Job title: Chief Development Officer


Next Generation Self-Replicating RNA Vectors to Enable New Approaches to Immunotherapy Synopsis 2:15 pm

Next generation synthetic srRNA vectors can lower dose by orders of magnitude compared to current srRNA designs Developing new srRNA products requires independent optimization of vectors, gene inserts, and delivery Improved srRNA bioactivity enable new approaches for strategies in vaccine developmentRead more

day: Day One Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.